Amylin Pharmaceuticals Inc trades in the stock market as ticker AMLN. Business Summary & Profile For Amylin Pharmaceuticals Inc.

Amylin Pharmaceuticals Inc

Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. The company’s products include BYETTA (exenatide) injection for the treatment of type 2 diabetes; and SYMLIN (pramlintide acetate) injection for the treatment of type 1 and type 2 diabetes. Its late stage development program in diabetes consists of BYDUREON (exenatide extended-release for injectable suspension), an investigational sustained-release medication for type 2 diabetes that is administered once a week. The company's obesity development program primarily focuses on two molecular franchises, including pramlintide, a synthetic amylin analog; and metreleptin, a recombinant leptin analog. It is developing pramlintide/metreleptin combination therapy, which is a product candidate in phase 2 for the treatment of obesity. The company markets its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers primarily in the United States. It has collaboration agreements with Eli Lilly and Company; Alkermes, Inc.; Takeda Pharmaceutical Company Limited; Biocon, Ltd.; and Juvenile Diabetes Research Foundation International Inc. The company was founded in 1987 and is based in San Diego, California.
www.amylin.com
Founded in 1987
LAST $17.76 USD
CHANGE TODAY -0.31 -1.72%
VOLUME 2.4M
As of 3:13 PM 02/17/12 All times are local (Market data is delayed by at least 15 minutes).

Snapshot of AMYLIN PHARMACEUTICALS INC (AMLN)

OPEN
$18.40
PREVIOUS CLOSE
$18.07
DAY HIGH
$18.45
DAY LOW
$17.73
52 WEEK HIGH
02/17/12 - $18.45
52 WEEK LOW
10/4/11 - $8.03
MARKET CAP
2.6B
AVERAGE VOLUME 10 D
5.6M
EPS TTM
$-3.67
SHARES OUTSTANDING
146.3M
AMLN Does Not Pay Dividends
P/E TTM
--
K = Thousands  M = Millions  B = Billions

related news for AMYLIN PHARMACEUTICALS INC (AMLN)

EU suggests new approval for diabetes drug Byetta
BRIEF: Amylin drug now available [Hamilton JournalNews, Ohio]

related news for AMYLIN PHARMACEUTICALS INC (AMLN)

Stock Picks: Google, Research In Motion
Fighting Takeovers by Playing the Debt Card
Why Clean Tech Is Taking Biotech's Shine
Inside Drugmakers' War on Fat

Key developments for AMYLIN PHARMACEUTICALS INC (AMLN)

Amylin Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011; Provides Earnings Guidance for the Year 2012; Plans to Segment its Commercial Organization into Two Discrete Units

Amylin Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2011. For the quarter, the company reported total revenue of $164.935 million against $174.190 million a year ago. Operating loss was $429.754 million against $10.309 million a year ago. Net loss was $461.471 million or $3.15 basic and diluted per share against net loss of $19.183 million or $0.13 basic and diluted per share a year ago. Non-GAAP operating income was $17.625 million against $22.928 million a year ago. Non-GAAP net income was $13.422 million or $0.09 basic and diluted per share against non-GAAP net income of $18.712 million or $0.13 basic and diluted per share a year ago. The improvements in its quarter-over-quarter non-GAAP operating results reflect decreased research and development expenses and decreased collaborative profit sharing, partially offset by increased selling, general and administrative expense. This improvement largely reflects the impact of the new economics for exenatide and the favorable disposition of certain cost-sharing disputes with Eli Lilly and Company. For the year, the company reported total revenue of $650.678 million against $668.813 million a year ago. Operating loss was $491.459 million against $126.744 million a year ago. Net loss was $543.399 million or $3.73 basic and diluted per share against net loss of $152.314 million or $1.06 basic and diluted per share a year ago. Non-GAAP operating income was $25.672 million against non-GAAP operating loss of $4.372 million a year ago. Non-GAAP net income was $13.461 million or $0.09 basic and diluted per share against non-GAAP net loss of $20.940 million or $0.15 basic and diluted per share a year ago. The company provided earnings guidance for the year 2012. For the year 2012, the company is expecting a non-GAAP operating loss of between $20 million and $40 million. The company expects net interest expense to be $165 million to $175 million, approximately $140 million of interest expense associated with the RSO. The company does not expect its capital expenditures to change significantly from $26.8 million in 2011. The company plans to segment its commercial organization into two discrete units, one focused on exenatide and the other on specialty and orphan products has been implemented now that BYDUREON has been approved. The company have completed the hiring of the 325 additional diabetes sales specialists for the exenatide commercial unit. And within the week, the company expects to complete the hiring of 65 additional diabetes sales specialists into its specialty and orphan commercial unit. The training of these new specialists has already commenced and it plans to have these new resources fully deployed by the 1st of March. The existing sales force of 325 diabetes sales specialists is already trained and priming the market for the availability of BYDUREON on February 17, 2012.

Amylin Pharmaceuticals, Inc. to Report Q4, 2011 Results on Feb 06, 2012

Amylin Pharmaceuticals, Inc. announced that they will report Q4, 2011 results at 5:00 PM, GMT Standard Time on Feb 06, 2012

Amylin Pharmaceuticals, Inc., Q4 2011 Earnings Call, Feb 06, 2012

Amylin Pharmaceuticals, Inc., Q4 2011 Earnings Call, Feb 06, 2012

AMLN Competitors

Company Last Change
Elan Corp PLC €9.57 EUR -0.324
Medicure Inc C$0.04 CAD 0.00
Oxford Biomedica PLC 2.90 GBp -0.025
Skyepharma PLC 31.00 GBp -3.62
Vernalis PLC 24.25 GBp -0.62
Market data is delayed at least 15 minutes.
 

Industry Analysis

Valuation AMLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x

AMLN

 | 

AMLN transactions

Type
Date
Target
No transactions in the last 6 months.
No related news found for this Amylin Pharmaceuticals Inc.

Write Comment Create Account
Subject Author
TOO FUNNY-kevindork and his 'buddy', haventaclue200
trying to 'STOP THE DEAL!!!!!!!!!!!!LOL These MUST be the ONLY TWO IDIOTS who haven&#...
looneybin_kev
How INSM bet worked out for ya, Fud ?
We shorted the h*lleuya out of it using money gained from AMLN. Thank you for your saving money....
havenger2001
Amylin's 2Q Results Sec Filing Today...
Amylin released its 2Q financial results after hours today in a Sec filing, but did not issue a pres...
kevinmik
What's AMLN's last trading day?
Anyone?...
neo17a
AMLN -Parkinson's 3/2013
So transparent- find this on AMLN's site? Who would know? Exendin-4 as a Treatment for P...
stuey.olsen
Amylin Went With Lower Offer To Save Their Jobs ?
I have to believe Amylin's ledership accepted a lower offer from Britol because Bristol offe...
kevinmik
Carl Icahn Is A Big AHole !
He did absolutely nothing to help or benefit Amylin Shareholders and he only lined his own wallet wi...
kevinmik
buy out
does anyone know when transaction will be complete and cash deposited....
hd_lowrider_stormy
Video Forecast
We are up over 36%, and my retirement savings have never looked better. <a href="ht...
yolonda_lily15
PSTI great cancer news again! See you at $20
Lots of big money flowing here....
beachdan1234
brokerage accounts with amln
post what happens to your brokerage accounts with amln today. so far UBS looks the same today as ye...
hd_lowrider_stormy
Unsolicited Bids ?
We should know by tomorrow if any unsolicited bids came in and are being considered. If not, so long...
kevinmik
Board Must Explore Unsolicited Bids !
If an unsolicited offer was made to Amylin that presents an opportunity to get a better deal for Amy...
kevinmik
Tender Offer Extension ?
Deadline to tender shares is 5:00 PM today and if for some reason everything did not go as planned f...
kevinmik
OT: Potential Alzheimer's treatment
<a href="http://www.bloomberg.com/news/2012-08-06/growth-hormone-may-stem-cognitive-decline-...
havenger2001
where is cash
The tender offer expired at 5:00 p.m., New York City time, on August 7, 2012. As a result of the ten...
hd_lowrider_stormy
Amylin will become a wholly-owned subsidiary of Bristol-Myers Squibb.
, Amylin will become a wholly-owned subsidiary of Bristol-Myers Squibb. All outstanding shares of co...
hd_lowrider_stormy
Bristol Meyer Buyout Is Done Deal !
It&#39;s official, Amylin is now part of Bristol Meyers as a majority of Amylin shares were tend...
kevinmik
will complete- Wednesday
NEW YORK (AP) -- Bristol-Myers Squibb Co. will complete its purchase of diabetes drug maker Amylin P...
hd_lowrider_stormy
BYE BYE Kevinmik!!
Your only purpose for your pathetic and idiotic existence is almost gone. If you had not been so per...
rr4ever@bellsouth.net
Stop Bristol Deal From Completing
and then Amylin should either seek a new buyer for a higher price or sign a new OUS partnership deal...
kevinmik
AMLN Files De-listing papers
The SEC has received your commitment papers kevinmik. Have a nice time in cyber-oblivion BONEHEAD. ...
rr4ever@bellsouth.net
Ode to Kevin
All alone am I ever since Amylin&#39;s bye bye All alone and no one to talk to. I&#3...
westcliffe7
Ahhh yesss,
time for us all to say - bye,bye .... it was a good ride, and now time to move on ........
win2few
$Should you sidestep AMLN ? Discover why.$
If you are looking for information on the stock market, then you might want to see this......... &...
markduke703

Quotes are delayed for NASDAQ, NYSE, OTC, OTCBB (Penny Stocks) and NYSE Amex when available. Quotes and other information supplied by independent providers and feeds. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Localnewsnor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing Localnews, you agree not to redistribute the information found therein.

Privacy Policy - WE KEEP YOUR PERSONAL DATA PRIVATE AND CONFIDENTIAL - Localnews is committed to protecting the privacy of all our visitors and subscribers. Your right to privacy is very important to us. When you choose to provide us with information about yourself, we recognize that you trust us to act in a responsible manner. SHARING OF INFORMATION - Localnews does not sell, rent, lease or share any user information that it has collected over this website.

@2012 www.localnewsnow.org - Contact Us / Privacy Policy